You are here:

Archived: losartan (Cozaar)

Advice

following a full submission:

losartan (Cozaar) is accepted for use within NHS Scotland for the treatment of hypertensive patients with left ventricular hypertrophy.

In a large international trial a losartan-based regimen reduced the risk of stroke compared with a beta-blocker-based regimen in patients with hypertension and left ventricular hypertrophy (LVH), who were without clinically evident vascular disease. There are no data on benefits relative to other antihypertensive agents. The trial data are included in the British Hypertension Society guidelines and reference should be made to these with regard to treatment choices for individual patients. An economic model indicates that a losartanbased regimen is cost-effective in patients with hypertension and LVH compared with a beta-blocker-based regimen.

Drug Details

Drug Name: losartan (Cozaar)
SMC Drug ID: 112/04
Manufacturer: MSD
Indication: hypertensive patients with left ventricular hypertrophy.
BNF Category:
Sub Category: 2.5 Hypertension and heart failure
Submission Type: Full submission
Status: Accepted
Date Advice Published: 9 August 2004

Current Advice

Full submission 8 November 2004

Back